Physician profile
Stacey Guan
NPI 1932429776
$729.33
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.19 · 2020: $260 · 2021: $123 · 2022: $261.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $135.20 | 2019-2020 | |
| Novo Nordisk INC | $102.48 | 2019-2021 | |
| Abbvie INC. | $96.93 | 2021-2022 | |
| Merz North America, INC. | $95.82 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $62.13 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.41 | 2020 | |
| Janssen Pharmaceuticals, INC | $31.46 | 2021 | |
| Merck Sharp & Dohme LLC | $26.10 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.39 | 2020-2021 | |
| Amarin Pharma, INC. | $24.90 | 2020-2021 | |
| Avion Pharmaceuticals | $23.62 | 2022 | |
| Biogen, INC. | $19.16 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.74 | 2019 | |
| Lilly USA, LLC | $16.06 | 2019 | |
| Mayne Pharma Commercial LLC | $14.93 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Guan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.